A relative newcomer to the Conejo Valley biotech landscape plans to follow up the region’s largest venture capital deal of 2019 with a $152 million public debut in 2020. Coming off a year of mega-deals in the biopharma space, Arcutis Biotherapeutics detailed plans to take its clinical-stage topical plaque psoriasis product public in filings with…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
